Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant and Concurrent Temozolomide for 1p/19q Non-Co-Deleted Anaplastic Glioma (CATNON; EORTC Study 26053-22054): Second Interim Analysis of a Randomised, Open-Label, Phase 3 StudyLancet Oncol 2021 May 14;[EPub Ahead of Print], MJ van den Bent, C Mircea S Tesileanu, W Wick, et al
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.